When ER+ tumours with HER2 gene amplification were treated with tamoxifen, the point estimate for the clinical response was poorer in HER2+ disease than in HER2− tumours, but this difference did not approach statistical significance (33% vs 49%; P = 0.49) (Ellis et al. 2006). The gene discussed is ERBB2; the disease is neoplasm.